Cyclerion Therapeutics Inc (CYCN)vsMerck & Company Inc (MRK)
CYCN
Cyclerion Therapeutics Inc
$2.98
-2.61%
HEALTHCARE · Cap: $12.90M
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3299850% more annual revenue ($65.77B vs $1.99M). MRK leads profitability with a 13.6% profit margin vs -264.7%. MRK earns a higher WallStSmart Score of 50/100 (D+).
CYCN
Avoid21
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.6%
Fair Value
$4.15
Current Price
$2.98
$1.17 discount
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -77.7% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CYCN
The strongest argument for CYCN centers on Price/Book.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CYCN
The primary concerns for CYCN are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
CYCN profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
CYCN carries more volatility with a beta of 1.77 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 21/100). CYCN offers better value entry with a 70.6% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cyclerion Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?